Crucell nabs $300M in Quinvaxem contracts

Dutch biotechnology firm Crucell won $300 million in contracts for it Quinvaxem pediatric vaccine, bringing total sales of the product to $800 million and pushing shares up by 3 percent. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.